Strategic Partnerships NeuraLight collaborates with leading research foundations and has active partnerships in Huntington's disease and other neurodegenerative areas, presenting sales opportunities to pharma, biotech, and contract research organizations seeking objective brain biomarkers for clinical trials.

Clinical Trial Readiness With involvement in Huntington's disease and Parkinson's progression studies and an upcoming hire of a prominent scientific advisor, NeuraLight is positioned to offer scalable biomarker endpoints and trial-ready measurement tools to drug developers aiming to accelerate neurodegenerative programs.

Regulatory & Validation Focus Recognition as a Prix Galien USA finalist and collaborations with CHDI Foundation indicate strong validation potential for clinical endpoints, providing a compelling case for presenting NeuraLight’s platform to regulatory teams seeking robust, well-vetted biomarkers.

Executive & Advisory Access New high-profile advisory leadership and connections to GLP-1 Parkinson’s research can open doors to enterprise pharma accounts, enabling co-development conversations around evidence generation, real-world data, and late-stage trial support.

Growth & Scale Signals Revenue range and ongoing funding support, combined with a growing network of neurologists and Nobel laureate endorsements, signal potential for upsell into larger biotech clients and multi-site deployment of NeuraLight’s brain-function measurement platform.